Background: Mr. Akkad Is A 76-Year-Old Iranian Male

Backgroundmr Akkad Is A 76 Year Old Iranian Male Who Is Brought To Yo

Mr. Akkad is a 76-year-old Iranian male whose family brought him to the clinic due to concerns about recent behavioral changes. Despite thorough evaluation, including laboratory tests and a CT scan of the head, no organic cause has been identified to explain his behavior. According to his family, these behaviors have been gradually worsening over the past two years. His personality has noticeably changed, with a decline in interest in religious activities and increased criticalness towards family and others. Previously serious matters now seem to evoke amusement or ridicule, indicating a significant shift in his social and emotional functioning.

Over the last two years, Mr. Akkad has exhibited increasing forgetfulness and difficulty retrieving words during conversations, often shifting abruptly to different topics. These changes are accompanied by a deterioration in his ability to recall previously familiar information, which has increasingly impacted his daily functioning. His family reports that these symptoms have progressively worsened, raising concerns about underlying neuropsychiatric conditions, possibly neurodegenerative diseases such as dementia or other cognitive disorders. It is essential to explore the differential diagnosis, underlying pathology, and appropriate management strategies for Mr. Akkad’s presentation, considering his cultural background, age, and personal history.

Paper For Above instruction

Mr. Akkad’s clinical presentation typifies a complex neuropsychiatric syndrome characterized by cognitive decline, personality changes, and behavioral disturbances. Given his age, the primary diagnostic considerations include neurodegenerative conditions such as Alzheimer’s disease, vascular dementia, Lewy body dementia, and frontotemporal dementia, as well as less common causes like depression, metabolic disturbances, or secondary effects of systemic illnesses. A comprehensive assessment combining detailed history-taking, neuropsychological testing, physical examination, and neuroimaging is essential to establish an accurate diagnosis.

Alzheimer’s disease (AD) remains the most prevalent cause of dementia in older adults, characterized by insidious onset and progressive memory impairment, followed by language deficits, executive dysfunction, and behavioral changes. The early personality shifts observed in Mr. Akkad, such as decreased interest in religious and social activities and increased criticism, are consistent with the behavioral variant of frontotemporal dementia (bvFTD), which typically presents with prominent personality and behavioral alterations before significant cognitive decline. This differentiation is critical, as management strategies and prognosis can differ markedly between these conditions.

Frontotemporal dementia is often diagnosed when behavioral and personality changes predominate, especially in younger elderly patients. It involves progressive atrophy of the frontal and temporal lobes, leading to disinhibition, apathy, and loss of empathy. On the other hand, vascular dementia results from cerebrovascular pathology, often with a stepwise decline and focal neurological deficits. Lewy body dementia can present with visual hallucinations, fluctuations in cognition, and parkinsonian features, although these are not explicitly mentioned in Mr. Akkad’s case. A detailed neuropsychological assessment can help differentiate these conditions by evaluating specific cognitive domains, such as executive function, language, and memory.

Imaging studies such as MRI may reveal characteristic patterns of brain atrophy. For instance, frontotemporal lobar degeneration typically shows asymmetric frontal and temporal cortical atrophy, while Alzheimer’s disease often involves the hippocampus and parietal lobes. Although Mr. Akkad’s CT scan was normal, MRI with high-resolution sequences could provide more detail regarding specific neuroanatomical changes. Additionally, laboratory investigations, including blood tests to rule out metabolic or infectious causes—like thyroid dysfunction, vitamin deficiencies, or syphilis—should be conducted.

Management of neurodegenerative dementias involves pharmacologic and non-pharmacologic strategies. Cholinesterase inhibitors and memantine are commonly used in Alzheimer’s disease to improve cognitive symptoms. For behavioral and psychological symptoms, behavioral therapies and support for caregivers are essential. For frontotemporal dementia, current pharmacologic options are limited and mainly symptomatic. Nonpharmacologic interventions focusing on behavioral management, environmental modifications, and caregiver education constitute critical components of comprehensive care.

Psychosocial support and counseling are paramount, especially considering the cultural context of the patient. Maintaining social engagement and providing religious and community support can improve quality of life. Family education about disease progression and strategies to handle behavioral changes can help reduce caregiver burden. In cases where behavioral disturbances are severe, pharmacological options such as selective serotonin reuptake inhibitors (SSRIs) may be considered to mitigate agitation or disinhibition.

Given the progressive nature of Mr. Akkad’s symptoms, regular monitoring and re-evaluation are necessary. Adjustments in management plans should be based on symptom progression and the patient’s and family’s evolving needs. Palliative care aspects, including planning for future care needs and addressing behavioral issues compassionately, are also integral components of holistic management.

References

• Bogey, S., & Gauthier, S. (2018). Dementia in the elderly. Clinics in Geriatric Medicine, 34(4), 615-629.
• Hodges, J. R., & Piguet, O. (2018). Frontotemporal Dementia: A Clinico-Pathological Overview. Brain Pathology, 28(2), 329-337.
• McKhann, G. M., et al. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association. Alzheimer's & Dementia, 7(3), 263-269.
• Seeley, W. W., et al. (2012). Frontotemporal Dementia: Clinical Features and Management. Journal of Geriatric Psychiatry and Neurology, 25(1), 45-52.
• Hansen, L. A., et al. (2016). Neuroimaging in Frontotemporal Dementia. Current Neurology and Neuroscience Reports, 16(12), 86.
• Kumar, N., et al. (2020). Differential Diagnosis of Dementia. Journal of Clinical Neuroscience, 78, 350-356.
• McMurtray, A. M., et al. (2008). Diagnosis and management of dementia. Mayo Clinic Proceedings, 83(3), 307-322.
• Rascovsky, K., et al. (2011). Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 134(9), 2456-2477.
• Shah, K., et al. (2020). Management strategies for behavioral and psychological symptoms of dementia. Clinical Interventions in Aging, 15, 867-882.
• Zhou, J., et al. (2019). Neuroimaging biomarkers of Alzheimer’s disease and other dementias. Frontiers in Aging Neuroscience, 11, 178.